COVID Antivirals in Korea: Paxlovid and Treatment Questions
If you have new COVID-19 symptoms and a higher risk of becoming seriously ill, contact a clinician promptly. The treatment choice depends on how long you have been ill, your risk factors, current medicines, kidney and liver function, and which treatment can be provided locally.
This guide discusses treatment access in Korea and uses U.S. regulatory material only where identified. It does not provide a personal prescription or a medicine-adjustment plan.
Why the first call should be early
Antiviral treatment is intended to reduce serious outcomes in eligible patients; it is not routinely needed by every otherwise healthy person with a positive test. U.S. FDA and CDC materials describe starting Paxlovid within five days of symptom onset and outpatient remdesivir within seven days. The Korean clinician must apply the Korean product label, treatment criteria, and available service to your case. Do not wait until the final day to enquire.
What changed in Korea in 2026?
In a February 26 announcement, KDCA said use of the government-supplied molnupiravir product Lagevrio would stop on March 17 because remaining stock was expiring. It described Paxlovid and remdesivir (Veklury) as the continuing options and advised referral to a facility able to administer remdesivir when appropriate.
The same notice reported that the Korean Paxlovid authorisation had expanded to include severe kidney impairment, including dialysis, with a clinician-adjusted regimen. Therefore, the blanket statement “kidney disease means Paxlovid can never be used” is not accurate. Kidney assessment and the exact prescription remain clinical decisions.
Bring these details to the consultation
| Information | Why it helps |
|---|---|
| Symptom start date and test result | Helps establish the treatment window and diagnosis |
| Age, pregnancy, immune conditions, and chronic illness | Helps assess risk and treatment suitability |
| All prescription drugs, over-the-counter medicines, and supplements | Allows an interaction review |
| Kidney or liver disease, dialysis, and recent results if available | May affect which medicine or regimen is appropriate |
| Ability to attend an infusion service | Helps assess whether an alternative is practical |
Do not stop another medicine on your own
Ritonavir can cause important interactions. A clinician or pharmacist must decide whether a medicine can be continued, temporarily changed, or makes a different COVID-19 treatment preferable. Bring the actual names or packaging; “a blood-pressure pill” is not enough to perform that review.
A negative test should not end the conversation
If symptoms and risk remain concerning, ask about the next diagnostic step. The negative-test guide explains when a result can miss an infection. Flu treatment uses different medicines and timing; see the flu antiviral guide.
When outpatient treatment is not enough
Severe breathing difficulty, persistent chest pain, new confusion, or inability to stay awake requires urgent assessment. Do not wait for a routine prescription appointment. While arranging care, reduce exposure to other people using the steps in our household guide.
Sources
- KDCA — Korean COVID-19 treatment supply and Paxlovid update, February 26, 2026 (PDF)
- CDC — outpatient treatment options and timing; U.S. guidance
- FDA — Paxlovid prescribing information; U.S. label
Source review: September 20, 2026. General educational information; this article does not replace medical care or individual advice. Local eligibility, availability, and administrative rules can change.
